Telo Genomics Corp. (TSXV:TELO)

Telo Genomics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Selling, General & Admin	1.28	1.38	1.44	1.52	1.03
Research & Development	0.91	1.32	1.28	1.29	1.08
Operating Expenses	2.19	2.7	2.72	2.82	2.11
Operating Income	-2.19	-2.7	-2.72	-2.82	-2.11
Interest Expense	-0.19	-0	-0	-0.01	-0.01
EBT Excluding Unusual Items	-2.38	-2.7	-2.72	-2.82	-2.11
Asset Writedown	-	-0.02	-	-	-
Other Unusual Items	0.05	-	0.01	-	-
Pretax Income	-2.33	-2.72	-2.71	-2.82	-2.11
Income Tax Expense	-0.02	-	-	-	-
Net Income	-2.31	-2.72	-2.71	-2.82	-2.11
Net Income to Common	-2.31	-2.72	-2.71	-2.82	-2.11
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	100	88	71	60	59
Shares Outstanding (Diluted)	100	88	71	60	59
Shares Change	14.33%	22.92%	18.67%	2.54%	25.11%
EPS (Basic)	-0.02	-0.03	-0.04	-0.05	-0.04
EPS (Diluted)	-0.02	-0.03	-0.04	-0.05	-0.04
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Free Cash Flow	-1.61	-2.33	-2.46	-2.7	-1.82
Free Cash Flow Per Share	-0.02	-0.03	-0.04	-0.04	-0.03
EBITDA	-2.17	-2.68	-2.68	-2.78	-2.05
D&A For EBITDA	0.02	0.01	0.04	0.03	0.06
EBIT	-2.19	-2.7	-2.72	-2.82	-2.11
Advertising Expenses	0.1	0.08	0.22	0.09	0.06

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error